2616 Stock Overview A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
CStone Pharmaceuticals Competitors Price History & Performance
Summary of share price highs, lows and changes for CStone Pharmaceuticals Historical stock prices Current Share Price HK$2.36 52 Week High HK$2.78 52 Week Low HK$0.80 Beta 0.22 1 Month Change 20.41% 3 Month Change 55.26% 1 Year Change 8.76% 3 Year Change -68.28% 5 Year Change -77.09% Change since IPO -81.65%
Recent News & Updates
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load? Dec 12
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
Non-Executive Director recently bought HK$1.9m worth of stock Nov 02
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK Oct 31 See more updates
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load? Dec 12
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
Non-Executive Director recently bought HK$1.9m worth of stock Nov 02
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK Oct 31
Key Executive recently bought HK$1.5m worth of stock Oct 23
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise Oct 04
Consensus revenue estimates decrease by 38%, EPS upgraded Aug 28
CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024 Aug 12
CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer Jul 26
CStone Pharmaceuticals Announces Change of Joint Company Secretary Jun 19
CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024 Jun 05
CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024 May 26
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website May 24
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified May 12
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 25
New minor risk - Financial data availability Apr 12
CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA Apr 09
Forecast to breakeven in 2026 Apr 03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer Mar 15
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop Mar 04
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet Jan 18
Consensus EPS estimates fall by 38% Jan 11
New minor risk - Share price stability Dec 12 CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma Dec 08
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma Oct 31
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma Oct 25
CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock Oct 12
The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26% Oct 04
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment? Oct 03
First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Sep 27
New major risk - Revenue and earnings growth Sep 04
CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application Jul 12
CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock Jul 10
CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023 Jul 01
CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer Jun 27
CEO, Senior VP & Chief Medical Officer recently bought HK$676k worth of stock Jun 27
CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023 Jun 07
CEO, Senior VP & Chief Medical Officer recently bought HK$285k worth of stock Jun 07
CEO, Senior VP & Chief Medical Officer recently bought HK$457k worth of stock May 17
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 27
Forecast to breakeven in 2024 Mar 16
No longer forecast to breakeven Feb 18 CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million. Feb 17
CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022 Feb 04
Cstone Pharmaceuticals Announces Management Changes Jan 19
CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China Jan 18
CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints Jan 03
CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist Dec 29
Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022 Dec 07
CEO, Senior VP & Chief Medical Officer recently bought HK$2.2m worth of stock Nov 22
Less than half of directors are independent Nov 16
Forecast to breakeven in 2024 Nov 11
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment? Oct 20
National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals Sep 14
CEO, Senior VP & Chief Medical Officer recently bought HK$668k worth of stock Sep 14
CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab Sep 13
CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022 Aug 16
CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022 Aug 08
CStone Pharmaceuticals Announces Executive Changes Jul 29
Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals Jul 16
CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China Jul 15
Forecast to breakeven in 2024 Jul 13
CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022 Jun 08
CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022 Jun 07 CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022
CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022 Jun 04
Less than half of directors are independent Jun 01
CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC May 17
CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo Apr 22
CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022 Apr 13
CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC Mar 31
CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022 Mar 23
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China Feb 17
CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia Feb 09 EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Sugemalimab Completed Patient Enrollment Jan 18 Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalimab in Stage IV Non-Small Cell Lung Cancer Published in the Lancet Oncology
CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate (ORR) in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) Jan 13
CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer Jan 05
CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In-Class ROR1-Targeting ADC by the U.S. Food and Drug Administration Jan 04
CStone Announces New Drug Approval of Precision Therapy AYVAKIT® (Avapritinib) in Hong Kong, China for the Treatment of PDGFRA D842V Mutant Gastrointestinal Stromal Tumors (GIST) Dec 28
CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy Dec 23
Chairman & CEO recently sold HK$10m worth of stock Dec 23
CStone Pharmaceuticals Announces New Drug Approval of Cejemly (Sugemalimab) in China to Potentially Reshape the Landscape of Immuno-Oncology Therapy in Lung Cancer Dec 22
Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt? Dec 17
Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal Antibody (Mab) Cs1002 in Combination with the Anti-Pd-1 Mab Cs1003 in Patients with Advanced Solid Tumors at ESMO 2021 Sep 21
EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demonstrating Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021 Sep 20
CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab in Patients with Stage III Non-Small Cell Lung Cancer in an Oral Presentation At ESMO Congress 2021 Sep 19 CStone Pharmaceuticals Receives China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0
CStone Pharmaceuticals Presents Registrational Bridging Study Data for Gavreto (Pralsetinib) Highlighting Efficacy and Safety in Chinese Patients with Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer at Iaslc Wclc 2021 Sep 09
National Medical Products Administration of China Accepts New Drug Application for Sugemalimab of CStone Pharmaceuticals as Consolidation Therapy Sep 02 Shareholder Returns 2616 HK Biotechs HK Market 7D -11.6% -2.9% 0.8% 1Y 8.8% -6.5% 21.1%
See full shareholder returns
Return vs Market: 2616 underperformed the Hong Kong Market which returned 21.1% over the past year.
Price Volatility Is 2616's price volatile compared to industry and market? 2616 volatility 2616 Average Weekly Movement 12.3% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 2616 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2616's weekly volatility (12%) has been stable over the past year.
About the Company CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
Show more CStone Pharmaceuticals Fundamentals Summary How do CStone Pharmaceuticals's earnings and revenue compare to its market cap? 2616 fundamental statistics Market cap HK$3.01b Earnings (TTM ) -HK$151.48m Revenue (TTM ) HK$485.95m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2616 income statement (TTM ) Revenue CN¥456.53m Cost of Revenue CN¥133.65m Gross Profit CN¥322.89m Other Expenses CN¥465.20m Earnings -CN¥142.31m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.11 Gross Margin 70.73% Net Profit Margin -31.17% Debt/Equity Ratio 65.5%
How did 2616 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 11:55 End of Day Share Price 2024/12/24 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CStone Pharmaceuticals is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ziyi Chen Goldman Sachs Ling Wang J.P. Morgan Sean Wu Morgan Stanley
Show 0 more analysts 
